BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

China BioPharma Ltd. Eyes Buyout of Tianyuan Biotech JV; Move Away from Vaccines


11/21/2007 7:21:09 AM

HANGZHOU, China, Nov. 20 /PRNewswire-FirstCall/ -- China Biopharma, Inc. today announced its new plan of operation to take closer control and to better improve its current operation results. The company also plans to move away from the increasingly competitive and low margin vaccine business, and to enter new specialty pharmaceutical products.

"We plan to take more control on the available cash in out subsidiaries and move into higher market potential and higher margin specialty pharmaceutical products," says Peter Wang, CEO and Chairman of Board. "And we are negotiating with a few global vaccine manufacturers now for carrying their higher margin products, in order to avoid direct competitions with other manufacturers."

Recent changes in vaccine sectors have resulted in more vaccine manufacturers entering into low margin vaccine business such as flu vaccine, thus creating severe competition among, and squeezed profit margin of, vaccine distributors such as China Biopharma. Besides moving away from the low margin vaccine business, the company also starts to enter specialty pharmaceutical products such as the recently released anti-viral products.

China Biopharma has most of its operation in China. Working to take direct control on subsidiaries' operation and financial management, the company plans to increase its shareholding in China Zhejiang Tianyuan Biotech Co., Ltd., and eventually to have 100% control and ownership in this joint venture. With internally available resources, there would be no need to raise additional capital to complete the transactions. This is expected to improve current performance and increase operation stability.

"This new direction is expected to preserve available cash position and give us more operation flexibility," says Chunhui Shu, the new interim Chief Financial Officer. "In view of improvement and progress on our current operation results, we have made this plan to take more effective steps to strengthen our control over operating subsidiaries, preserve cash, apply available resources to, and refocus on higher margin, less competitive products with greater market potential."

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

ir@chinabiopharma.nethttp://www.chinabiopharma.net

CONTACT: George Ji of China Biopharma, Inc., +1-609-651-8588,
ir@chinabiopharma.net

Web site: http://www.chinabiopharma.net/



Read at CNN
Read at BioSpace.com

CNN
BioSpace.com
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES